Cardinal Health (CAH) valuation is being reevaluated following significant share price rally in recent months.
First Trust Advisors and Invesco Ltd increased their stakes, while
American Century Companies reduced theirs. Following strong Q1 results for the Fiscal Year 2026, the company's earnings and revenue surpassed estimates leading to a further optimism. Various specialty pharma moves might have significant implications on the company’s
stock valuation. Cardinal is expanding its pharmaceutical distribution with new facilities in
Indianapolis and at-Home Solutions in
Texas and California. Notably, it recently announced the addition of
Solaris Health, a leading urology MSO, to The Specialty Alliance. Despite mixed market reactions, its shares reached a 52-week high based on encouraging earnings. Further, the company affirms long-term growth and raises outlook. Cardinal Health is eyeing automation and expanding its global device rollout. The company's recent actions have attracted attention from institutional owners, and it might be undervalued in the current market.
Cardinal Health CAH News Analytics from Thu, 01 May 2025 07:00:00 GMT to Sat, 06 Dec 2025 09:29:43 GMT -
Rating 8
- Innovation 5
- Rumor -5
